Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Agreement completed for rights to vaccines
March 10th, 2005
BioVeris Corporation (BIOV) announced that it has completed an agreement with the National Research Council of Canada (NRC) for a license to patent rights to candidates for a group B streptococcus (GBS) Type II and Type V vaccine and a group B meningococcus (GBM) vaccine. Under the agreement with the NRC, the company acquired worldwide, exclusive rights to commercialize products for possible use in the prevention, diagnosis and treatment of disease caused by GBS, a leading cause of sepsis, pneumonia, and meningitis among newborns. The company received similar worldwide rights, with the exclusion of Canada, to NRC's GBM vaccine technologies for the...
Source: Women's Health Weekly (2005-03-10)
|
